Lopinavir/ritonavir in the treatment of HIV-1 infection: a review

References

• Abbott LaboratoriesKaletra® (lopinavir/ritonavir) tablets and oral solution. Prescribing information [online] Accessed 20 March 2008. URL: http://www.kaletra.com
   Google Scholar
• BongiovanniMBiniTAdorniF2003Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutationsAntivir Ther82091412924537
   PubMed Web of Science ®Google Scholar
• BongiovanniMCicconiPLandonioS2005Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individualsInt J Antimicrob Agents26889115878262
   PubMed Web of Science ®Google Scholar
• CahnPVillacianJLazzarinA2006Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV infected patients: 24 weeks results of RESIST 2 trialClin Infect Dis4313475617051504
   PubMed Web of Science ®Google Scholar
• ClotetBBellosNMolinaJM2007Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomized trialsLancet36911697817416261
   PubMed Web of Science ®Google Scholar
• CohenCNieto-CisnerosLZalaC2005Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trialCurr Med Res Opin2116839216238909
   PubMed Web of Science ®Google Scholar
• CrommentuynKMLMulderJWMairuhuATA2004The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1 infected patientsAntivir Ther97798515535416
   PubMed Web of Science ®Google Scholar
• CunhaAMHagemannCCSimonesRS2007Effects of lopinavir-ritonavir combined therapy during the rat pregnancy. Morphological and biochemical aspectsEur J Obstet, Gynecol Reprod Biol13360316989938
   PubMed Web of Science ®Google Scholar
• DeeksSGSmithMHolodniyM1997HIV-1 protease inhibitors. A review for cliniciansJAMA277145538990341
   PubMed Web of Science ®Google Scholar
• DelfraissyJFFlandrePDelaugerreC2008Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naïve HIV-infected patientsAIDS223859318195565
   PubMed Web of Science ®Google Scholar
• DragstedUBGerstoftJYouleM2005A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trialAntivir Ther107354316218173
   PubMed Web of Science ®Google Scholar
• EronJJrYeniPGatheJJr2006The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trialLancet3674768216890834
   PubMed Web of Science ®Google Scholar
• FDA/Center for Drug Evaluation and ResearchDrugs@FDA [online] Accessed 25 March 2008. URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda.
   Google Scholar
• FischlMACollierACMukherjeeAL2007Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimenAIDS213253317255739
   PubMed Web of Science ®Google Scholar
• FlexnerC1998HIV-Protease inhibitorsN Engl J Med3381281939562584
   PubMed Web of Science ®Google Scholar
• GatheJJrCooperDAFarthingC2006Efficacy of protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24 week analysis from RESIST-1 trialClin Infect Dis4313374617051503
   PubMed Web of Science ®Google Scholar
• Gazzard B on behalf of BHIVA Writing CommitteeBritish HIV Association Guidelines for treatment of HIV infected adults with antiretroviral therapy (2006). [Online] [Accessed 20March 2008] URL: http://www.bhiva.org.
   Google Scholar
• Gonzalez-RequenaDNunezMJimenez-NacherI2004Short communication: liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfectionAIDS Res Hum Retroviruses2069870015307912
   PubMed Web of Science ®Google Scholar
• GrinsztejnBNguyenBYKatlamaC2007Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trialLancet3691261917434401
   PubMed Web of Science ®Google Scholar
• GulickRMHuXJFiscusSA2000Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359J Infect Dis18213758411023461
   PubMed Web of Science ®Google Scholar
• HaerterGManfrasBJMuellerM2004Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavirAIDS18952515060446
   PubMed Web of Science ®Google Scholar
• HammerSMBassettRSquiresKE2003A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavirAntivir Ther85071814760884
   PubMed Web of Science ®Google Scholar
• HammerSMSaagMSSchechterM2006Treatment for Adult HIV infection. 2006 recommendations of the International AIDS Society-USA PanelJAMA2968274316905788
   PubMed Web of Science ®Google Scholar
• JohnsonMAGatheJCJrPodzamczerD2006A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimenJ Acquir Immune Defic Syndr431536016951643
   PubMed Web of Science ®Google Scholar
• JohnsonMGrinsztejnBRodriguezC2005Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failuresAIDS196859415821394
   PubMed Web of Science ®Google Scholar
• JohnsonVABrun-VezinetFClotetB2006Update of the Drug Resistance Mutations in HIV-1: Fall 2006Top HIV Med141253016946457
   PubMedGoogle Scholar
• KempfDJIsaacsonJDKingMS2001Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patientsJ Virol757462911462018
   PubMed Web of Science ®Google Scholar
• KempfDJIsaacsonJDKingMS2002Analysis of virologic response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-infected patients receiving lopinavir/ritonavirAntivir Ther71657412487383
   PubMed Web of Science ®Google Scholar
• KingMSBernsteinBMWalmsleySL2004Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy – naive patientsJ Infect Dis190280415216462
   PubMed Web of Science ®Google Scholar
• KleinCEChiuYLAwniW2007The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effectJ Acquir Immune Defic Syndr444011017224848
   PubMed Web of Science ®Google Scholar
• KumarGNDykstraJRobertsEM1999Potent inhibition of the cytochrome P450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A prospective drug-drug interactionDrug Metab Dispos27902810421617
   PubMed Web of Science ®Google Scholar
• KumarGNJayantiVKJohnsonMK2004Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs and humansPharm Res2116223015497688
   PubMed Web of Science ®Google Scholar
• LafeuilladeAHittingerGPhilipG2004Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra)HIV Clin Trials5392815682352
   PubMed Web of Science ®Google Scholar
• LetendreSLvan der BrandeGHermesA2007Lopinavir and ritonavir reduces the HIV RNA level in cerebrospinal fluidClin Infect Dis4515117
   Web of Science ®Google Scholar
• LimMLMinSSEronJJ2004Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 inductionJ Acquir Immune Defic Syndr3610344015247556
   PubMed Web of Science ®Google Scholar
• LuoMPShenYRodeRMcMillanF2004Substitution to lopinavir/ritonavir is associated with improved patient-reported fatigue in HIV positive patients experiencing side effects related to their protease inhibitor/non-nucleoside reverse transcriptase inhibitorValue Health7360
   Web of Science ®Google Scholar
• MadrugaJVBergerDMcMurchieM2007Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trialLancet370495817617272
   PubMed Web of Science ®Google Scholar
• McCance-KatzEFRaineyPMFriedlandG2003The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patientsClin Infect Dis374768212905130
   PubMed Web of Science ®Google Scholar
• MolinaJMAndrade-VillanuevaJEchevarriaJ2008Efficacy and safety of once-daily atazanavir/ritonavir compared to twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabinein ARV-naive HIV-1-infected subjects: The CASTLE Study, 48-week results [abstract]15th Conference on Retroviruses and Opportunistic InfectionsBostonFeb 3–6 2008 Abstract 37.
   Google Scholar
• MoltoJSantosJRNegredoE2007Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practiceJ Antimicrob Chemother60436917556354
   PubMed Web of Science ®Google Scholar
• MurphyRLBrunSHicksCB2001ABT-378/ritonavir puls stavu-dine and lamivudine for the treatment of antiretroviral naïve adults with HIV infection: 48 week resultsAIDS15F1911192874
   PubMed Web of Science ®Google Scholar
• MurphyRLda SilvaBAHicksCB2008Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patientsHIV Clin Trials911018215977
   PubMed Web of Science ®Google Scholar
• OldfieldVPloskerGL2006Lopinavir/ritonavir. A review of its use in the management of HIV infectionDrugs6612759916827606
   PubMed Web of Science ®Google Scholar
• OrtizRDejesusEKhanlouH2008Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48AIDS2213899718614861
   PubMed Web of Science ®Google Scholar
• PalaciosRVergaraSRiveroA2006Lower incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavirHIV Clin Trials73192317197379
   PubMed Web of Science ®Google Scholar
• Panel on clinical practices for treatment of HIV infection. Guidelines for use of antiretroviral agents in HIV infected adults and adolescents [online] Accessed 20 March 2008. URL: http://AIDSinfo.nih.gov.
   Google Scholar
• ParkinNTChappeyCPetrpoulosCJ2003Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistanceAIDS179556112700444
   PubMed Web of Science ®Google Scholar
• PatersonDLSwindellsSMohrJ2000Adherence to protease inhibitor therapy and outcomes in patients with HIV infectionAnn Intern Med133213010877736
   PubMed Web of Science ®Google Scholar
• PaulsenDLiaoQFuscoG2002Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremiaAIDS Res Hum Retroviruses181011912396453
   PubMed Web of Science ®Google Scholar
• PollardRBThompsonMHicksM2004Phase 3 comparison of lopinavir/ritonavir vs investigator-selected protease inhibitor in single PI experienced NNRTI-naïve patients: 48 week results of study M98-888 [poster]7th International Congress on Drug Therapy in HIV InfectionGlasgowNov 14–18 2004 Abstract No PI.3.2 plus poster.
   Google Scholar
• PulidoFArribasJRDelgadoR2008Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIVAIDS22F1918097218
   PubMed Web of Science ®Google Scholar
• RanaKZDudleyMN1999Human immunodeficiency virus protease inhibitorsPharmacotherapy1935599917077
   PubMed Web of Science ®Google Scholar
• RiddlerSAHaubrichRDiRenzoG2008Class-sparing regimens for initial treatment of HIV-1 infectionN Engl J Med3582095210618480202
   PubMed Web of Science ®Google Scholar
• Saez-LlorensXViolariADeetz Co2003Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected childrenPediatr Infect Dis J222162312634581
   PubMed Web of Science ®Google Scholar
• SaxPE2005Top stories of 2004. Back to the future: lopinavir/ritonavir as “monotherapy”AIDS Clin Care17415717366
   PubMedGoogle Scholar
• ShamHLKempfDJMollaA1998ABT-378, a highly potent inhibitor of the human immunodeficiency virus proteaseAntimicrob Agents Chemother423218249835517
   PubMed Web of Science ®Google Scholar
• ShuterJSSarloJKanmazTJ2007HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%J Acquir Immune Defic Syndr454817460469
   PubMed Web of Science ®Google Scholar
• TaburetAMRaguinGLe TiecC2004Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virusClin Pharmacol Ther753102315060509
   PubMed Web of Science ®Google Scholar
• Third World NetworkAs AIDS drugs fail, few have any alternative [online] August 23, 2006. URL: http://www.twnside.org.sg/title2/health.info/twninfohealth032.htm.
   Google Scholar
• van der RystECooperDKonourinaI2007Efficacy of Maraviroc in combination with at least one other potent new antiretroviral drug: 24-week combined analysis of the MOTIVATE 1 and 2 studies [abstract]4th IAS Conference on HIV Pathogenesis, Treatment and Prevention Abstract no. WEPEB115LB.
   Google Scholar
• von HentigNBabacanEStaszewskiS2007Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patientsAntivir Ther1212374618240863
   PubMed Web of Science ®Google Scholar
• WalmsleySBernsteinBKingM2002Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infectionN Engl J Med34620394612087139
   PubMed Web of Science ®Google Scholar
• WalmsleySRuxrungthamLSlimJ2007Saquinavir/r (SQV/r) bid versus lopinavir/r (LPV/r) bid, plus emtricitabine/tenofovir (FTC/TDF) qd as initial therapy in HIV-1-infected patients: The Gemini Study11th European AIDS ConferenceMadrid, SpainOctober 24–27, 2007.
   Google Scholar
• WalmsleySLCotteLRusconiS2007Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scoresAIDS212245818090054
   PubMed Web of Science ®Google Scholar
• World Health Organization2006Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approachGenevaWHO Press
   Google Scholar
• YilmazAStahleLHagbergL2004Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimenScand J Infect Dis36823815764168
   PubMed Web of Science ®Google Scholar